ALSO NOTED: Houston develop plots biotech park; Galvus wins EU nod; OncoMethylome inks deal with Abbott; and much more...

> A Houston developer has acquired Tanox's old headquarters--110,000 square feet on 24 acres--and plans to develop it as a biotechnology park. Tanox developed the asthma drug Xolair. Report

> European regulators are recommending approval of Novartis' Galvus. A diabetes drug. Novartis expects to launch the therapy in the first half of next year. Report

> Belgium's OncoMethylome Sciences has struck a deal with Abbott Laboratories to help profile tumors, testing its DNA methylation biomarkers on Abbott's biological samples. Release

> Chutes & Ladders: AlgoNomics has promoted Philippe Stas to CEO. Release

> Novartis and Merck are refocusing their sales efforts away from the doctors who write the prescriptions and toward the insurers that pay for them. Report

> One of Shire's shareholders is crying foul at the drug maker's big management reshuffling announced last week. Report

> Ex-FDA chief David Kessler got the boot at University of California-San Francisco, where he has been dean of the medical school since 2003. Report

> Bristol-Myers Squibb said it was going to retrench, and so it is. The company announced this morning that it would sell its medical imaging unit to the private equity firm Avista Capital Partners for about $525 million. Report


And Finally... A researcher is criticizing the way the U.S. is monitoring the spread of H5N1 in migratory birds, saying U.S. efforts could easily miss the virus as it makes its way into the country. Release